The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2025 | Could HMGA1 be used as a prognostic biomarker for MPN disease progression?
In this video, Linda Resar, MD, Johns Hopkins Medical Institute, Baltimore, MD, comments on the potential use of high mobility group A1 (HMGA1) as a prognostic biomarker for disease progression in patients with myeloproliferative neoplasms (MPNs). This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Indeed, it is up-regulated when the stem cells acquire a JAK mutation. We also know it’s higher as the disease progresses. So because it’s sort of a level of expression, the higher the level certainly would correlate with a poor phenotype. And so I think it is a very interesting question. We haven’t examined that rigorously, but we do know, for example, even in platelets, so platelet transcriptomes, we can see higher levels of HMGA in more advanced disease...
Indeed, it is up-regulated when the stem cells acquire a JAK mutation. We also know it’s higher as the disease progresses. So because it’s sort of a level of expression, the higher the level certainly would correlate with a poor phenotype. And so I think it is a very interesting question. We haven’t examined that rigorously, but we do know, for example, even in platelets, so platelet transcriptomes, we can see higher levels of HMGA in more advanced disease. And so I think it’s quite an interesting question because platelets and blood cells can easily be taken. All of our patients get their blood drawn frequently. And so we could look at levels. The thing we don’t know is whether or not the high level precedes the progression or if it’s concurrent with progression. But certainly when we see it in our patient samples using diverse approaches to look at gene expression, it correlates with poorer outcomes in advanced disease.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
NIH grants and Investigator-Initiated Grants from PharmaEssentia.
